ABSTRACT The effect of the selective thromboxane A2 synthetase inhibitor OKY-1581, a pyridine derivative [sodium (E)-3-(4-(3-pyridylmethyl)phenyl)-2-methyl-2-propenoate], on thromboxane B2 and 6-keto-prostaglandin F,, levels and platelet aggregation was studied in human volunteers. To clarify its effectiveness as an enzyme inhibitor, OKY-1581, at doses of 17, 83, 167, 417, 833, and 1667 gig/kg (n = S for each group), was injected intravenously, or was infused (10 ,ug/kg/min; n = 5) over 3 hr on 3 successive days. OKY-1580 (OKY-1581 free acid) was rapidly converted to its main ,Boxidized product, OKY-1565, and its reduced form, OKY-1558. During the study, plasma thromboxane B2 levels, inhibition of thromboxane B2 production in serum, and inhibition of rabbit platelet thromboxane A2 synthetase were monitored continuously. Twenty-five minutes after the injection of the above doses, plasma thromboxane B2 levels decreased by 4 + 7%, 40 + 14%, 57 + 7%, 68 6%, 93 + 5%, and 96 + 5% (mean SD), respectively. Thromboxane B2 production in serum was decreased by 2 + 8%, 70 + 10%, 75 8%, 81 + 10%, 95 10%, and 96 ± 8%, respectively, and rabbit platelet thromboxane A2 synthetase by 2 ± 7%, 52 + 8%, 79 ± 10%, 80 ± 9%, 96 + 8%, and 95 ± 7%. These parameters returned to the control levels 24 hr after the injection. During infusion of OKY-1581 at a rate of 10 gg/kg/min for 3 hr, plasma thromboxane B2 levels decreased significantly, and inhibition of thromboxane B2 production in serum and of rabbit platelet thromboxane A2 synthetase was also significant. Intravenous infusion of this drug reduced platelet aggregation induced by arachidonate (2 mM) significantly. In serum of incubated whole blood, after the treatment with OKY-1581, serum 6-keto-prostaglandin F,, production was increased significantly. OKY-1581 caused no untoward symptoms or changes in hemodynamic parameters or electrocardiographic or laboratory results, including those for bleeding time and coagulation. In cardiovascular diseases in which thromboxane A2 may be involved in the pathogenesis, this selective inhibitor of thromboxane A2 synthetase may become a useful drug because it inhibits thromboxane A2 production and arachidonate-induced platelet aggregation.
ficial effect of making more endoperoxides available for conversion to prostacyclin, is desirable. This potential benefit cannot be obtained with such antiplatelet drugs as aspirin, which primarily inhibits cyclooxygenase.l Therefore, inhibition of thromboxane A2 synthetase seems to be an attractive new approach to the control of thromboembolic disease. This report evaluates the effect of a selective inhibitor of thromboxane A2 synthetase in human volunteers.
Materials and methods
Experimental subjects. Normal healthy men, 25 to 40 years old and weighing 50 to 60 kg, gave informed consent for this study. Before OKY-1581 was administered, each patient was screened for medical illness; a history and biochemical and hematologic profile were obtained and each patient underwent physical, chest x-ray, and electrocardiographic examinations.
Subjects with any clinically relevant disease or laboratory test abnormality were excluded. Subjects were requested to abstain from all drugs and were admitted to Kyoto University Hospital the night before the study. They were fed fat-free diets during the study to minimize lipid interference with platelet aggregation studies; two 21-gauge butterfly needles, one for drug administration and the other for blood sampling, fitted with threeway stopcocks were inserted into the veins of both forearms 1 hr before drug administration to eliminate the need for frequent venipuncture. These systems were kept patent with 0.6 ml of heparinized saline (100 U/ml).
Drug. OKY-1581 was supplied by Ono Pharmaceutical Company (Osaka, Japan). Continuous infusion was delivered by means of an infusion pump (Nipro Company; Osaka, Japan). The diluent was normal saline. Drug solutions, prepared each day of administration, were stable for at least 24 hr at room temperature. The structure of OKY-1581, sodium (E)-3-(4-(3-pyridylmethyl)phenyl)-2-methyl-2-propenoate, is illustrated in figure 1 . OKY-1581 was injected intravenously (,ug/kg) or was infused for 3 hr on 3 successive days (10 ,g/kg/min).
Clinical tests. Vital signs and electrocardiograms were recorded by nurses at frequent intervals. Biochemical and hematologic examinations were performed at both the initiation and termination of the study.
Platelet aggregation tests. At scheduled times during the study, platelet-rich plasma (PRP) was prepared from whole blood (3.15 ml) anticoagulated with 3.8% citrate (0.35 ml). Samples were centrifuged in plastic tubes successively at 300 and 2000 g for 10 min to collect, respectively, PRP and plateletpoor plasma (PPP).3 PRP was diluted with PPP as needed to give a final count of 300,000/mm3.
Aggregation was induced in 0.24 ml aliquots of PRP by the addition of 0.02 ml of arachidonate (2 mM B2 . The final assay volume was 0.5 ml. The mixture was incubated for 16 hr at 40 C. Antibodybound thromboxane B2 was separated from the unbound compound with 0.5 ml of dextran-coated charcoal (mixture of 3.75 mg of dextran and 37.5 mg of charcoal per milliliter) by centrifugation at 1000 g for 10 min, and the amount of antibodybound thromboxane B2 in the supematant was determined. Validation of this assay was by dilution and recovery studies. All assays had a 80% recovery. The sensitivity of the assay was 10 pg/ml plasma. The cross-reactivity of this antibody was as follows: thromboxane B2 100%, prostaglandin D2 10%, prostaglandin E2 0.2%, prostaglandin A2 0.2%, prostaglandin F 0.2%, and 6-keto-prostaglandin Fia 0.2%. When [3H]-prostaglandin D2 was used, 95% of prostaglandin D2 added to plasma was found to be excluded by the above sample purification. The ability of the assay to detect known amounts of thromboxane B2 is shown in figure 2 . Plasma thromboxane B2 concentrations were expressed in picograms per milliliter. In our laboratory, this method has a coefficient of variation of 5.3%. The normal value was 90 + 25 pg/ml (n = 50).
Inhibition of thromboxane B2 production in serum. Se- THERAPY AND PREVENTION-THROMBOSIS rum thromboxane B2 production levels were measured in serum derived from 1 ml of whole blood allowed to clot at 370 C for 1 hr in plain glass tubes (ng/3 x 105 platelets).' The details of the radioimmunoassay were the same as those of the assay used for determination of plasma thromboxane B2 levels. The effect of plasma containing OKY-1581 and its metabolites on the inhibition of formation of thromboxane B2 in vitro was expressed as percentage inhibition. The normal value of serum thromboxane B2 production levels was 68 + 25 ng/3 x 105 platelets (n = 50).
6-Keto-prostaglandin FVa production in serum. Levels of serum 6-keto-prostaglandin Fia production were obtained in serum derived from 1 ml of whole blood allowed to clot at 370 C for 1 hr in plain glass tubes (ng/ml). During purification on the reverse-phase column before radioimmunoassay, 5% ethanol was used instead of 15% ethanol in this assay. 6-Keto-prostaglandin F,i antiserum was purchased from Cappel Laboratories.
[3HI-6-Keto-prostaglandin F,, (120 to 180 Ci/mmol) was obtained from New England Nuclear Corporation. Authentic 6-keto-prostaglandin F,, was supplied by Ono Pharmaceutical Company. The cross-reactivity of this antibody was a follows:
6-keto-prostaglandin Fi, 100%; prostaglandin A1, A2, B1, DHF2a, DHKE2Q, D2, and thromboxane B2 less than 0.01%; prostaglandin EB 0.1%; prostaglandin E2 1.2%; prostaglandin Fia 1.9%; and prostaglandin F2a 2.6%. The normal value was 0.5 ± 0.13 ng/ml (n = 20).
Inhibition of rabbit platelet thromboxane A2 synthetase. (500 mg), was added to 1 ml of plasma and acidified by IN HCI to pH 3.0. Samples were transferred to an Amberlite XAD-2 column. The eluent was evaporated to dryness by methanol. After the addition of 0. IN HCl and ethyl acetate (1/1, vol/vol), the extract was treated with diazomethane and evaporated to dryness. The methyl esters of OKY-1581 and its metabolites in methanol were analyzed by gas chromatography-mass spectrometry. A JEOL 20 KP gas chromatograph and JMSD-100 mass spectrometor (Nippon Denshi Company, Japan) were used. The column was 2 mm x 1.5 m inner diameter, of 3% OV-17, and operated at 2350 C. The helium pressure was 1.6 kg/cm2. The electron energy was 20 eV and the ion source temperature was 270°C.
Thromboxane A2. Thromboxane A2 was generated by incubating 1 ,ug of prostaglandin H2 in acetone with 410,g horse Results Figure 3 shows dose-response curves of OKY-1581 for inhibition of plasma thromboxane B2, inhibition of thromboxane B2 production in serum, and inhibition of rabbit thromboxane A2 synthetase. Values were obtained 25 min after the injection of drug. These data show dose-related changes in these three parameters. OKY-1580, the free acid form of OKY-1581, was transformed in plasma into OKY-1558, 3-(4-(3-pyridylmethyl)phenyl)-2-methyl-propionic acid, by reduction, or into OKY-1565, 4-(3-pyridylmethyl) benzoic acid, by fl-oxidation in plasma. Figure 4 shows the metabolic fate of the three compounds after the injection of 417 ,ug/kg. Two hours after injection, OKY-1580 disappeared, and OKY-1565 appeared at 4.8 min and persisted for 24 hr. OKY-1558 was detectable for only 1 hr.
The effectiveness of OKY-1581 as a thromboxane A2 synthetase inhibitor was tested with the following three parameters: plasma thromboxane B2 levels ( figure 5, A) , inhibition of thromboxane B2 production in serum ( figure 5, B) , and inhibition of rabbit platelet thromboxane A2 synthetase (figure, 5 C). After the injection, peak effects on plasma thromboxane B2 levels were obtained at 25 min. During the infusion of OKY-1581 at a rate of 10 ug/kg/min for 3 hr on 3 successive days (n = 5), plasma thromboxane B2 levels decreased significantly (percentage of inhibition 2 hr after the start of the infusion: 82 ± 5%, 78 ± 4%, and 78 ± 2%), and thromboxane B2 production in serum(91 ± 5%, 88 + 6%, and87 ± 5%) andrabbit platelet thromboxane A2 synthetase (90 ± 10%, 89 ± 10%, and 88% ± 7%) were also significantly inhibited. Changes in platelet aggregation induced by arachidonate (2 mM) were as follows: 31.0 + 28.0% vs 6.2 ± 5.1%, 42.6 + 28.2%vs 1.7 ± 2.9%, and39.4 ± 6.8% vs 1.8 ± 1.6%. In a placebo study, the vehicle (glycine buffer, pH 9.1) was given by a single injection or in a 3 hr infusion. Placebo had no effect on the three parameters.
During the administration of OKY-1581, arachidonate-induced platelet aggregation decreased significantly (table 1) . However, when studied in vitro only, OKY-1581 at final concentrations of more than 8.3 mg/ml suppressed the platelet aggregation induced by thromboxane A2, which was generated by prostaglandin H, and platelet microsome thromboxane A2 synthetase. Figure 6 illustrates the effect of OKY-1581 on 6- keto-prostaglandin F,, production in serum 1 hr after the treatment. OKY-1581 increased 6-keto-prostaglandin F,, production in serum significantly.
' | There were no clinically relevant changes in heart 500 1,000
5,000 9/kg rate or blood pressure, and no adverse symptoms or signs. Routine laboratory tests, including those for bleeding time, showed no important abnormalities. Thromboxane A2, an extremely potent inducer of platelet aggregation and smooth muscle contraction, is produced by activated platelets.' Excess formation of thromboxane A2 is considered to play an important role in the pathophysiology of thromboembolic diseases, especially in the development of arteriosclerotic or cardiovascular diseases.1' 2 To control or depress the formation of thromboxane A2, aspirin and other nonsteroidal anti-inflammatory drugs that react with cy-500 1,000 5,000 9gkg clooxygenase may be used.7-9 However, the inhibition of cyclooxygenase activity concomitantly depresses the formation of prostacyclin. Thus, the selective inhibition of thromboxane A2 synthetase, which catalyzes the synthesis of thromboxane A2 from prostaglandin H2, is considered to be an attractive new therapeutic approach. Thromboxane A2 synthetase is inhibited by various pharmacologic agents including imidazole"' and its derivatives,4' 1 l' pyridine and its derivatives,'2 9,1 1-azoprosta-5, 13-dienoic acid,10 and l la-carbathromboxane A2 analogue.'3 We studied the effects of the selective inhibition of thromboxane A2 synthesis on thromboxane A2 formation and platelet aggregation, cyclin metabolite. 'I However, the levels and even the existence of 6-keto-prostaglandin F,, in plasma are now being questioned. 4. 15 Figure 6 shows that the selective inhibition of thromboxane B2 formation concomitantly redirected platelet endoperoxides into 6-keto-prostaglandin F, production in serum. This increased production of serum 6-keto-prostaglandin F, could occur in monocytes. 16 However, treatment with aspirin, a cyclooxygenase inhibitor, would inhibit both thromboxane B2 formation and 6-keto-prostaglandin F, production in serum.
After injection, OKY-1581 is rapidly converted to OKY-1565 or 1558. The 50% inhibitory concentrations for these three substances in the purified thromboxane B2 synthetase system are 6, 260, and 27 nM, respectively. In our studies in vivo, arachidonate-induced platelet aggregation was inhibited by OKY-1581, although in vitro, OKY-1581 (8.3 mg/ml) antagonized thromboxane A2-induced platelet aggregation. Thus, high concentrations of OKY-1581 may have a dual action: inhibition of thromboxane A2 formation and antagonism of platelet aggregation caused by thromboxane A2. This dual action of thromboxane A2 synthetase has been reported previously. 17 The mechanism of the inhibition of platelet aggregation is unknown; OKY-1581 may cause irreversible damage in platelets, but this antiaggregatory dose of OKY-1581 results in levels nowhere near those obtained in vivo.
In the treatment of patients in whom thromboxane A2 might be involved in the pathophysiology of cardiovascular disease, the inhibition of thromboxane A2 synthetase may become a useful method. However, in clinical use, we must be aware of the adverse effects that may arise with the long-term inhibition of thromboxane A2 synthetase.
